Approximately 12.5% of in-hospital patients on the continent are gravely ill. This number equates to roughly one in eight ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...